Firma PELOBIOTECH – mainevents

PELOAcademy | Human Respiratory Tissue Models to study Odorant Metabolism (Webinar | Online)

Firma PELOBIOTECH Webinar 8. Oktober 2024animal-free, epitheliacells, Fraunhofer-Institut für Silicatforschung, Human Respiratory, Odorant Metabolism, primary cells, primarycells, Regenerative Therapien, Tissue Model, Würzburg

presented by Dr. rer. nat. Maria Steinke, UK Würzburg, Klinik und Poliklinik für HNO-Krankheiten, plastische und ästhetische Operationen und Fraunhofer-Institut für Silicatforschung ISC, Translationszentrum für Regenerative Therapien, Würzburg

Nasal xenobiotic metabolizing enzymes (XMEs) are important for the sense of smell. They protect the nasal tissue from potentially harmful volatile compounds and can influence odorant availability and quality. We cultured primary nasal epithelial cells and fibroblasts at the air-liquid interface to obtain three-dimensional human respiratory tissue models.

Join this webinar to – learn how our respiratory tissue models are built and characterized – find out if the respiratory mucosa contributes to food odorant metabolism through XME activity – discuss human airway tissue models to reduce animal experiments

#tissuemodels #airway #animal-free #respiratory #fibroblasts #primarycells #epitheliacells

Eventdatum: Mittwoch, 04. Dezember 2024 10:00 – 11:00

Eventort: Online

Firmenkontakt und Herausgeber der Eventbeschreibung:

PELOBIOTECH GmbH
Behringstrasse 10
82152 Planegg/Martinsried
Telefon: +49 (89) 51777140
Telefax: +49 (89) 51777160
http://www.pelobiotech.com

Weiterführende Links

Für das oben stehende Event ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben)
verantwortlich. Dieser ist in der Regel auch Urheber der Eventbeschreibung, sowie der angehängten
Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH
übernimmt keine Haftung für die Korrektheit oder Vollständigkeit des dargestellten Events. Auch bei
Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit.
Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung
ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem
angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen
dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet

PELOAcademy | A new threat: Cross Contamination in Cell Culture (Webinar | Online)

Firma PELOBIOTECH Webinar 8. Oktober 2024Cell Culture, Cross Contamination, innovation, innsbruck, iPS, primary cells, Stem Cells, Webinar

presented by Prof. Dr. Gerhard Gstraunthaler, emer. Medizinische Universität Innsbruck

Instances of cross-contamination of cell lines are more widespread than generally appreciated. Despite periodic reminders from concerned cell culturists, the problem continues and even seems to be neglected by the scientific community. While, in the past, due to the widespread use of animal cell lines, inter-species contaminations were most common, in biomedical research today, intra-species contaminations between human cell cultures have become a new threat. In this webinar, Gerhard will talk about the scale of the problem, the major pitfalls that can lead to cross-contamination, and the methods that can be used to avoid it altogether.

Eventdatum: Dienstag, 05. November 2024 10:00 – 11:00

Eventort: Online

Firmenkontakt und Herausgeber der Eventbeschreibung:

PELOBIOTECH GmbH
Behringstrasse 10
82152 Planegg/Martinsried
Telefon: +49 (89) 51777140
Telefax: +49 (89) 51777160
http://www.pelobiotech.com

Weiterführende Links

PELOAcademy|Compatibility of hiPSC-derived cardiomyocytes in cardiac safety assessment of drugsafety (Webinar | Online)

Firma PELOBIOTECH Webinar 8. Oktober 2024Cardiac toxicity, cardio, cardiomyocytes, cardiosight, drug safety, heart, innovation, nexel, pharma, toxicity

presented by Dr. Jieun An, Nexel Co., Ltd., Republic of Korea

Cardiac toxicity is a major cause of compound attrition during drug development as well as for the withdrawal of drugs already on the market. Although ICH S7B guideline has successfully reduced hERG-related risk issues, concerns remain regarding the accuracy of the assay, as hERG blockade does not always correlate with QT prolongation in patients. With recent advances in stem cell technology, it is now possible to generate human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) that recapitulate the native behavior and accurately assess the proarrhythmic potentials of candidate drugs. These cells are being actively studied with high-throughput technology, particularly in connection with the ICH guideline revision (CiPA initiative), for their potential as novel assays for preclinical toxicity testing.

In this context, we aim to introduce NEXEL’s Cardiosight^®-S (hiPSC-CMs), aligning with the updated ICH E14/S7B guidelines, and provide practical examples of its applications. Notably, Cardiosight^®-S exhibits a purity exceeding 95% of cardiac markers and demonstrates a dose-dependent response to drugs targeting electrophysiological ion channels, suggesting high physiological relevance of the cells. By utilizing Cardiosight^®-S, we optimized the evaluation of cardiac safety across four platforms (Axion MEA, Nanion FLEXcyte, CardioExcyte, and Agilent CardioECR) to measure field potential and impedance. In summary, toxicity test using Cardiosight^®-S offers a promising alternative for determining cardiac safety risks earlier in drug discovery and preclinical studies to assess compounds’ cardiac liability.

Eventdatum: Mittwoch, 16. Oktober 2024 10:00 – 11:00

Eventort: Online

Firmenkontakt und Herausgeber der Eventbeschreibung:

PELOBIOTECH GmbH
Behringstrasse 10
82152 Planegg/Martinsried
Telefon: +49 (89) 51777140
Telefax: +49 (89) 51777160
http://www.pelobiotech.com

Weiterführende Links

PELOAcademy | Scalable EV Isolation & High-Quality Purification:Integrating Charge-Based Filtration (Webinar | Online)

Firma PELOBIOTECH Webinar 8. Oktober 2024EV, EV isolation, Exo-Filter, extracellular Vesicle, Korea, Microgentas, pharma, primary cells, reseach, Webinar

presented by Prof. Dr. Sehyun Shin, Korea University & CEO, Microgentas Inc., Seoul, Korea

This webinar will showcase Microgentas‘ innovative approaches for scalable EV isolation and high-quality purification, focusing on the integration of charge-based filtration (ExoFilter) with other technologies like TFF and LipoFilter. Attendees will learn how ExoFilter, combined with Tangential Flow Filtration (ExoTFF), and the lipoprotein-specific LipoFilter, optimize EV yield and purity.

he session will cover practical strategies to overcome process challenges and achieve consistent, high-quality results in large-scale EV preparations, providing participants with the tools to enhance their isolation processes.

Eventdatum: Dienstag, 15. Oktober 2024 10:00 – 11:00

Eventort: Online

Firmenkontakt und Herausgeber der Eventbeschreibung:

PELOBIOTECH GmbH
Behringstrasse 10
82152 Planegg/Martinsried
Telefon: +49 (89) 51777140
Telefax: +49 (89) 51777160
http://www.pelobiotech.com

Weiterführende Links

PELOAcademy | Engineering Cardiac Microtissues for Cell Replacement Therapy (Webinar | Online)

Firma PELOBIOTECH Webinar 4. April 202423. Mai 2024cardiac, microtissue, therapy, Webinar

presented by Dr. Kurt Pfannkuche, Universität zu Köln

Induced pluripotent stem cells (iPSCs) can be differentiated into heart muscle cells in vitro and open up new possibilities for the development of therapies for myocardial infarction. However, the transplantation of pure cardiac muscle cells from iPSCs has the disadvantage that only a small proportion of the cells remain in the tissue. The transplantation of micro-tissues containing other cardiac cell types in addition to cardiac muscle cells appears more promising. The production of these microtissues under defined, serum-free culture conditions can be carried out on a laboratory scale using established methods. However, new approaches are required for the production of micro-tissues on the scale required for (pre-)clinical research. The presentation will show approaches for the experimental production of cardiac microtissues for cell therapy.

Eventdatum: Mittwoch, 10. April 2024 10:00 – 11:00

Eventort: Online

Firmenkontakt und Herausgeber der Eventbeschreibung:

PELOBIOTECH GmbH
Behringstrasse 10
82152 Planegg/Martinsried
Telefon: +49 (89) 51777140
Telefax: +49 (89) 51777160
http://www.pelobiotech.com

Weiterführende Links

First Conference “Advancements in Animal-Free Research and Translational Medicine” in Munich (Konferenz | Krailling)

Firma PELOBIOTECH Konferenz 4. April 202423. Mai 2024berndgiebel, cellculture, Event, EVs, GMP, Networking, PELOBiotech, pharma, primarycells, Stemcells

Our conference „Advancements in Animal-Free Research and Translational Medicine“ will promote novel non-animal approaches that are essential for progress in translational medical research. The focus will be on the development and validation of serum substitutes, paving the way for ethical and scientifically sound alternatives. After an overview of the principles of cell culture and stem cells, presentations will be given on applications and hands-on experiences in the lab. Speakers will highlight the use of Fetal Bovine Serum (FBS), Serum Alternatives, and Serum-free Media with case studies of serum-free, xeno-free, and defined in vitro applications.

Numerous innovative applications will be highlighted throughout the day. We will discuss the translational applicability and challenges associated with mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in the therapeutic context. Moreover, we will look at the utilization of human adipocyte spheroids as an innovative model for obesity research to provide insights into the in vitro capabilities for physiologically relevant conditions. Lastly, the scalability of cardiac organoids for preclinical applications will be demonstrated, establishing their importance for cardiovascular research and pharmacological advances. Alongside fantastic talks, the conference will be a fruitful environment for discussions and the fostering of new collaboration.

Discussions will extend from classic 2D cell culture work onto humanized multi-organoid systems for disease modeling and pharmacodynamics, illustrating their potential for simulating multi-layered disease states and therapeutic interventions.

Let´s exchange ideas and solutions, and find out more about applications, including the efficacy, reproducibility, and potential impact of serum substitutes on experimental outcomes. Through the multiple interdisciplinary discussions and presentations, this conference presents the perfect opportunity to get together and network with other scientists and experts in the field.

Upon request, we will be more than happy to provide certificates of registration and attendance.

Location: IZB (Innovation Center Biotechnology), Ellipse 1+2, Am Klopferspitz 19, 82152 Planegg, Germany
Registration: Early Bird and PELOClub Members: 349 Euros (register by April 30, 2024) | Standard fee: 399 Euros
Upon request, certificates of registration and attendance will be provided.
Registration: Email conference@pelobiotech.com; https://www.pelobiotech.com/resources/conferences.html

Eventdatum: Donnerstag, 27. Juni 2024 09:00 – 17:00

Eventort: Krailling

Firmenkontakt und Herausgeber der Eventbeschreibung:

PELOBIOTECH GmbH
Behringstrasse 10
82152 Planegg/Martinsried
Telefon: +49 (89) 51777140
Telefax: +49 (89) 51777160
http://www.pelobiotech.com